Fine-mapping analysis including over 254,000 East Asian and European descendants identifies 136 putative colorectal cancer susceptibility genes
- PMID: 38670944
- PMCID: PMC11053150
- DOI: 10.1038/s41467-024-47399-x
Fine-mapping analysis including over 254,000 East Asian and European descendants identifies 136 putative colorectal cancer susceptibility genes
Abstract
Genome-wide association studies (GWAS) have identified more than 200 common genetic variants independently associated with colorectal cancer (CRC) risk, but the causal variants and target genes are mostly unknown. We sought to fine-map all known CRC risk loci using GWAS data from 100,204 cases and 154,587 controls of East Asian and European ancestry. Our stepwise conditional analyses revealed 238 independent association signals of CRC risk, each with a set of credible causal variants (CCVs), of which 28 signals had a single CCV. Our cis-eQTL/mQTL and colocalization analyses using colorectal tissue-specific transcriptome and methylome data separately from 1299 and 321 individuals, along with functional genomic investigation, uncovered 136 putative CRC susceptibility genes, including 56 genes not previously reported. Analyses of single-cell RNA-seq data from colorectal tissues revealed 17 putative CRC susceptibility genes with distinct expression patterns in specific cell types. Analyses of whole exome sequencing data provided additional support for several target genes identified in this study as CRC susceptibility genes. Enrichment analyses of the 136 genes uncover pathways not previously linked to CRC risk. Our study substantially expanded association signals for CRC and provided additional insight into the biological mechanisms underlying CRC development.
© 2024. The Author(s).
Conflict of interest statement
Antoni Castells is a consultant to Bayer Pharma AG, Boehringer Ingelheim and Pfizer Inc. for work unrelated to this manuscript. Anna Shcherbina is an employee at Insitro, including consulting fees from BMS. Heather Hampel is SAB for Invitae Genetics, Promega and Genome Medical, Stock/Stock options for Genome Medical and GI OnDemand. Rish K Pai collaborates with Eli Lilly, AbbVie, Allergan, Verily and Alimentiv, which includes consulting fees (outside the submitted work). Stephanie A Bien has a financial interest in Adaptive Biotechnologies. Stephen B Gruber is co-founder, Brogent International LLC. One of Zsofia K Stadler’s immediate family members serves as a consultant in ophthalmology for Alcon, Adverum, Gyroscope Therapeutics Limited, Neurogene and RegenexBio (outside the submitted work). Victor Moreno has research projects and owns stocks of Aniling. The remaining authors declare no competing interests.
Figures


References
Publication types
MeSH terms
Grants and funding
- R01 CA188214/CA/NCI NIH HHS/United States
- UL1 TR001863/TR/NCATS NIH HHS/United States
- U01 CA261339/CA/NCI NIH HHS/United States
- U01 CA206110/CA/NCI NIH HHS/United States
- R01 CA269589/CA/NCI NIH HHS/United States
- R01 CA263318/CA/NCI NIH HHS/United States
- P30 CA068485/CA/NCI NIH HHS/United States
- P01 CA196569/CA/NCI NIH HHS/United States
- R01CA188214/U.S. Department of Health & Human Services | National Institutes of Health (NIH)
- P30 ES010126/ES/NIEHS NIH HHS/United States
- R37 CA227130/CA/NCI NIH HHS/United States
- P30 CA008748/CA/NCI NIH HHS/United States
- U01 CA272529/CA/NCI NIH HHS/United States
- 001/WHO_/World Health Organization/International
- R37CA227130/U.S. Department of Health & Human Services | National Institutes of Health (NIH)